Your session is about to expire
← Back to Search
Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet for Pharmacokinetics
Study Summary
This trial is investigating whether baclofen and chlorzoxazone, when given together, are more effective than either drug given alone for spinocerebellar ataxia types 1 and 2. The trial will also evaluate the pharmacokinetic properties of the two drugs and assess any adverse events attributed to them.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA cleared Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet for use?
"This medication, which is currently in Phase 1 testing, has received a score of 1 for safety. This is due to the lack of extensive data supporting both its efficacy and safety."
For which patients is this research project intended?
"Up to 15 patients that match the following profile can join this trial: Between 18-50 years old, currently have pharmacokinetics, healthy male or female, non-smoker without significant medical or mental health history, not regularly taking prescription medication."
Does this research project have an age limit for participants?
"According to the inclusion criteria, only patients aged 18-50 can enroll in this clinical trial. There are 3 other studies for children under the age of 18 and 31 trials for seniors above 65 years old."
Are people with the condition being sought out for this research project?
"That is correct, the clinicaltrials.gov website has information indicating that this study is presently looking for patients. This trial was initially posted on 4/27/2022 and was most recently updated on 4/27/2022. A total of 15 patients will be admitted at 1 location."
Share this study with friends
Copy Link
Messenger